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Management of malaria
Key components of successful management are 
early and accurate diagnosis (Table 1) and prompt 
treatment with effective drugs.
Treatment should ideally be based on confirmed 
parasitological diagnosis.[1,2] Microscopy of Giemsa-stained 
thick and thin blood smears remains the diagnostic mainstay.[3] 
Rapid antigen detection diagnostic tests (RDTs) are more widely 
accessible than expert microscopy, provide prompt results and 
are adequately sensitive for Plasmodium falciparum infections. 
However, RDTs cannot quantify parasite density (so do not detect 
hyperparasitaemia that indicates severe malaria) and are less 
sensitive for non-falciparum species than for falciparum infections. 
RDTs are unsuitable for monitoring treatment response because of 
antigen persistence.[4] A negative (rapid or microscopy) test does 
not exclude malaria; repeat testing within 8 - 24 hours, without 
attempting to coincide with fever peak timing, is mandatory 
until a positive result or an alternative definitive diagnosis is 
achieved. Blood smears should be checked for malaria whenever 
thrombocytopenia is unexpectedly identified. Test any patient 
with unexplained fever for malaria, even in the absence of a travel 
history. Occasionally, infected mosquitoes are transported from 
endemic areas in suitcases and vehicles (Odyssean malaria).[5] All 
malaria cases must be notified to local health authorities.
Treatment of malaria
The choice and route of treatment depends primarily on disease 
severity, which is often underestimated. Uncomplicated malaria is 
symptomatic infection without signs of severity or evidence of vital 
organ dysfunction. Persistent vomiting, clinical jaundice, change in 
mental state or increase in respiratory rate constitutes severe malaria 
(Table 2).[6,7]
Treat uncomplicated malaria with artemether-lumefantrine 
(Coartem) (Table 3).[2] For optimal absorption it must be taken 
with milk or fat-containing food. Adequate fluids, temperature 
control with paracetamol, and careful follow-up are important. Avoid 
non-steroidal anti-inflammatory agents. Patients should respond 
clinically and parasitologically within 24 - 48 hours. Consider 
poor compliance, misdiagnosis and possible drug resistance if 
no significant improvement occurs within 72 hours. Artemether-
lumefantrine remains efficacious in South Africa (SA),[8,9] with no 
reports of artemisinin resistance in Africa as yet. In the rare event of 
artemether-lumefantrine treatment failure despite full compliance, 
give a full directly observed 7-day course of oral quinine (plus 
doxycycline or clindamycin) in hospital.
Oral quinine, combined with 7 days of doxycycline, remains an 
alternative to artemether-lumefantrine (Table 4), but compliance is 
poor. In pregnancy or children aged <8 years, substitute clindamycin 
for doxycycline (Table 4). Doxycycline or clindamycin add no early 
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Table 1. Diagnosis of malaria
Keep a high index of suspicion for malaria in travellers to, or residents of, malaria transmission areas presenting with fever or other ’flu-like 
illness, irrespective of the time of year, intensity of transmission or use of chemoprophylaxis. Always take an adequate travel history.
Typical presentation: paroxysms of fever and rigors in adults, also headache, myalgia, loss of appetite, nausea and vomiting. In young children, 
fever, lethargy, poor feeding, vomiting and diarrhoea are most common.
Important differential diagnoses: meningitis, African tick-bite fever, typhoid, viral haemorrhagic fever, trypanosomiasis.
Progression to severe disease may be rapid, particularly in non-immune and immune-compromised persons, young children and pregnant 
women.
Often missed in patients with comorbid disease.
Frequently misdiagnosed in pregnancy, requiring differentiation from pregnancy complications including intrauterine and urinary tract infections.
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treatment benefit, so are started only once symptoms improve, as 
gastrointestinal side-effects may exacerbate those of quinine.
Drug interactions
Concomitant use of certain other drugs (e.g. efavirenz, rifampicin) 
may alter blood concentrations of artemether-lumefantrine and 
quinine. There is no evidence of the clinical significance of 
these interactions, but full adherence and fat co-administration is 
advised, and response to treatment should be monitored particularly 
carefully.
Pregnancy
First trimester. Supervised 7-day course of oral quinine plus 
clindamycin.
Second and third trimesters. Artemether-lumefantrine is con-
sidered safe and efficacious.
Large adults
Artemether-lumefantrine is registered in SA only for use in patients 
weighing ≤65 kg. Minimal pharmacokinetic data exist for larger 
patients; one study suggests a trend towards increased risk of 
treatment failure in patients >80 kg.[10] Again, adequate adherence 
and fat co-administration is important, with careful monitoring of 
response. If adherence is assured, consider administering the same 
total dose over 5 days (dosing at 0, 8, 24, 48, 72 and 96 hours).
Recommendations for non-falciparum malaria
Malaria species should be confirmed by a reliable laboratory. Non-
falciparum infections are usually uncomplicated, but occasionally 
produce severe illness. Use artemether-lumefantrine for initial 
therapy of uncomplicated P. vivax and P. ovale infections. To prevent 
relapses, this should be followed by a course of primaquine after 
excluding glucose-6-phosphate dehydrogenase (G6PD) deficiency. 
Table 2. Clinical and laboratory criteria for severe malaria 
(any one or combination of these criteria applies)
Clinical
Impaired consciousness, multiple convulsions
Respiratory distress, acidotic breathing, pulmonary oedema
Circulatory collapse
Jaundice
Bleeding
Prostration
Laboratory
Hypoglycaemia (blood glucose <2.2 mmol/L)
 Acidosis (plasma bicarbonate <15 mmol/L or serum lactate  
>5 mmol/L) 
Hepatic transaminases >3 times normal
 Renal impairment (serum creatinine >265 µmol/L or rapidly 
rising creatinine or urine output <400 mL/day in an adult)
Haemoglobin <5 g/L
Parasitaemia ≥5%
≥5% neutrophils contain malaria pigment
Presence of schizonts of P. falciparum in peripheral blood smear
Table 3. Dosing schedule for artemether-lumefantrine (Coartem)
Body weight (kg)
Time of dosing (hours) and number 
of tablets
0 8 - 12 24 36 48 60 
5 - 14 1 1 1 1 1 1
15 - 24 2 2 2 2 2 2
25 - 34 3 3 3 3 3 3
≥35 4 4 4 4 4 4
Table 4. Dosing schedule for oral quinine with doxycycline or 
clindamycin
Drug Schedule
Oral quinine 10 mg/kg 8-hourly for 7 days
Doxycycline 200 mg stat, thereafter 100 - 200 mg once daily, or 
3.5 mg/kg once daily for 7 days
Clindamycin 10 mg/kg bd for 7 days
Table 5. Dosing schedule and adverse effects for mefloquine, doxycycline and atovaquone-proguanil
Chemoprophylactic Schedule Adverse effects
Mefloquine (Lariam, Mefliam) Weekly, starting 1 - 2 weeks before travel, weekly 
while there and continue for 4 weeks after
Adults: 250 mg weekly
Children: 5 mg/kg weekly
Not recommended for children <3 months or 
<5 kg
Gastrointestinal, headache, dizziness, imbalance, 
mood changes, insomnia, nightmares, and rarely, 
psychosis. Increased risk of eye disorders
Contraindications: epilepsy, neuropsychiatric 
disorders, those who require fine motor 
co-ordination, divers and pilots
Doxycycline (daily) Daily, starting 1 day before travel, daily while 
there and continue for 4 weeks after
Adults: 100 mg daily
Not recommended for children <8 years
Skin photosensitivity, oesophagitis, upper 
gastrointestinal symptoms, vaginal candidiasis or 
diarrhoea (normal flora disruption)
Atovaquone-proguanil (Malanil, Numal) Daily, starting 1 day before travel, daily while 
there and continue for 1 week after
Adults: 1 tablet daily
Children >11 kg: Malanil Paediatric at prescribed 
dose per body weight
Adverse reactions uncommon; include headache, 
nausea, vomiting, abdominal pain, diarrhoea
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The recommended dose in children is 0.25 - 0.3 mg/kg daily for 
14 days, and that for adults is 15 mg daily for 14 days. Currently 
primaquine is only available on a named-patient basis with Section 
21 MCC approval.
Severe malaria (Table 5)
Severe malaria is a medical emergency requiring prompt parenteral 
treatment, intensive nursing care, and careful monitoring and 
management of complications.[6.7] Intravenous artesunate (2.4 mg/kg 
Table 6. Drug choice according to patient factors
Patient factor Mefloquine Doxycycline Atovaquone-proguanil
Pregnancy – avoid travel to 
malaria areas.
Now recommended for all 
trimesters[12,13] if travel is 
necessary.
Contraindicated Contraindicated owing to lack of 
data.
Young children – avoid taking 
children <5 years to high-risk 
areas.
Can be used in children  
>3 months or >5 kg. Generally 
well tolerated by children.
Use only in children >8 years. Paediatric tablets can be given to 
children >11 kg. Breaking of tablets 
is not recommended.
Persons requiring long-term 
prophylaxis
Can be used for up to 3 years. 
Longer-term use may be 
justified by risk of malaria.
Can be safely used for up to 2 
years. Longer term use may be 
justified by risk of malaria.
Can be used confidently for up to 
1 year. Longer-term use may be 
justified by risk of malaria.
HIV-positive (on ARVs) Best option
ARVs = antiretrovirals.
Fig. 1. Malaria risk map for SA (adopted 2014).
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at 0, 12 and 24 hours, then daily until the patient is able to tolerate 
oral treatment) is preferred treatment, but is currently unregistered 
and only available on a named-patient basis with Section 21 MCC 
approval.[2,11] When intravenous artesunate is not promptly available, 
intravenous quinine (with an initial loading dose of 20 mg/kg and 
then maintenance doses of 10 mg/kg, each dose slowly infused over 
at least 4 hours) is initiated urgently and given 8-hourly until oral 
treatment is tolerated. Follow with a complete course of artemether-
lumefantrine.[2] Reassess frequently to ensure that all complications 
are promptly detected and optimally managed.
Critical issues in management of severe malaria
Hypoglycaemia. Urgently exclude (or administer empiric glucose) 
if there is a depressed level of consciousness or convulsions. Repeat 
glucose monitoring 4-hourly.
Renal failure. This is a frequent, early complication in 
adults. Severe malaria requires careful fluid management, with 
frequent measurement of renal function (urea, electrolytes and 
creatinine), ongoing monitoring of urine output and judicious fluid 
administration. Strictly avoid overhydration, as the acute respiratory 
distress syndrome is a common and difficult-to-treat complication, 
particularly in pregnancy.
Prevention of malaria
Prevention of mosquito bites is the mainstay of malaria prevention. 
Malaria-transmitting mosquitoes generally bite at night, so people 
in malaria-endemic areas should ideally remain indoors from dusk 
to dawn, and sleep under insecticide-treated bednets in rooms 
with screened windows and doors. Fig. 1 shows endemic areas in 
SA; residents and travellers in these areas should take necessary 
precautions to avoid mosquito bites.
Effective repellents contain DEET (diethyl toluamide). Use 
products containing 20 - 50% DEET for long-lasting protection for 
adults and children aged >2 months. Products containing >50% 
DEET have no additional benefit. Avoid applying to eyes or mouth.
Additionally, travellers to malaria-endemic areas should use 
chemoprophylaxis depending on the malaria risk assessment. Three 
similarly effective chemoprophylactic agents are currently registered 
in SA (Table 5), all requiring a doctor’s prescription. Selection should 
be based on patient factors (Table 6) and which option is likely to be 
best tolerated for optimal adherence.
Scope of protection
Chemoprophylactics are most effective against parasite asexual blood 
stages. While they will prevent initial illness caused by all species, 
they will not prevent relapses due to P. vivax and P. ovale.
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